Focus on acquisitions result in growth for Karo Pharma
After starting out as a small research company, Karo Pharma has expanded through organic growth and strategic acquisitions, quickly positioning itself as one of the leading pharmaceutical companies in the Nordics and currently strengthening its position across other European markets.
Since the founding of Karo Pharma in 1987 we have both expanded and fundamentally changed the direction of our business, while aiming to improve the health and well-being of patients and consumers.
Today, Karo Pharma is a pharmaceutical company that focuses on the sales and marketing of prescription drugs (Rx) and over the counter healthcare products (OTC) which are sold at pharmacies and in retail stores. Our products are available in over 60 countries, where they help giving patients and consumers better access to effective treatments. Since the population in the Nordic countries as well as the rest of the Western world is ageing, we predict that the demand for our products will be substantial for the foreseeable future.
Karo Pharma is expanding both organically and through opportunistic acquisitions which have positive synergy effects for our organization. We primarily focus on acquiring and effectively integrating established brands with positive cash flows and stable earning potential. We also invest in innovative projects and partnerships with low development risk and short time to market. This strategy has resulted in solid profitability during the past few years and will play a pivotal role in strengthening our presence in Europe by positioning Karo Pharma as an attractive partner.
The success of the past few years had not been possible without our capable and passionate team members. Karo Pharma has more than 150 employees, spread across our HQ in Stockholm along with offices in 7 other countries.
We improve the health and well-being for patients and consumers by making our differentiated, high quality, branded medicines and healthcare products accessible and available.
To become a Northern European leader in branded medicines and consumer health products with distinctive positions in the categories in which we compete.